《大行報告》麥格理降藥明生物(02269.HK)評級至「中性」 目標價下調至38元
麥格理發表評級報告,藥明生物(02269.HK)下調今年非新冠病毒收入增長預測,預料調整後淨利潤呈單位數跌幅。該行將公司今年收入增長預測由29%下調至12%,並預期今年國際財務報告準則純利下跌25%、調整後淨利潤下跌9%。
該行將公司在2023年至25年收入預測分別下調13%至25%,而各年毛利率預測則分別下調至40%、42%及43.5%,調整後盈利預測則降25%、降29%及降25%。
該行將其目標價由52元下調至38元,評級由「跑贏大市」降至「中性」。(ca/cy)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.